Statements (33)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:brand
gptkb:drug |
| gptkbp:activeIngredient |
cabazitaxel
|
| gptkbp:administeredBy |
intravenous infusion
|
| gptkbp:approvalYear |
2010
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
L01CD04
|
| gptkbp:CASNumber |
183133-96-2
|
| gptkbp:chemicalClass |
taxane
|
| gptkbp:combines |
gptkb:prednisone
|
| gptkbp:contraindication |
severe hepatic impairment
|
| https://www.w3.org/2000/01/rdf-schema#label |
Jevtana
|
| gptkbp:indication |
metastatic castration-resistant prostate cancer
|
| gptkbp:KEGGID |
D06574
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Sanofi
|
| gptkbp:MedlinePlusID |
a610024
|
| gptkbp:pregnancyCategory |
D
|
| gptkbp:prescribes |
patients previously treated with docetaxel
|
| gptkbp:PubChem_CID |
gptkb:CHEMBL1201197
6918153 DB06772 |
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
gptkb:anemia
nausea vomiting diarrhea fatigue neutropenia |
| gptkbp:UNII |
Q1Y9K2F0BA
|
| gptkbp:usedFor |
prostate cancer
|
| gptkbp:bfsParent |
gptkb:赛诺菲
|
| gptkbp:bfsLayer |
6
|